Tag: Piramal Enterprises

MUMBAI: Ind-Swift Labs said it will sell its active pharmaceutical ingredient (API) and contract research & manufacturing services (CRAMS) business to India Resurgence Fund - an investment platform promoted by Piramal Enterprises and Bain Capital - for Rs 1,650 crore. The acquisition will be routed through IndiaRF's portfolio company Synthimed Labs. The Ind-Swift scrip touched a 52-week high, closing 2% higher at Rs 22.5 on the BSE, after the company's board approved the slump sale of its business on Wednesday. The equity value of the transaction is worth...